[Cardiovascular effects of VDR and CaSR activation]

Area of Science:

• Nephrology and Cardiovascular Medicine
• Mineral Metabolism and Bone Disease

Context:

• Cardiovascular complications are the leading cause of death in patients undergoing chronic dialysis.
• Vascular calcification, particularly in vessel walls, is a significant finding associated with increased cardiovascular mortality.
• Existing treatments for chronic kidney disease patients on dialysis have not fully addressed cardiovascular risks.

Purpose:

• To review the potential benefits of vitamin D receptor (VDR) activators in reducing morbidity and mortality in dialysis patients.
• To explore the role of calcium-sensing receptor (CaSR) activators in improving clinical outcomes for dialysis patients.
• To provide an updated perspective on VDR and CaSR activators for managing cardiovascular and all-cause mortality in dialysis populations.

Summary:

• Vascular calcification is prevalent in uremic patients on chronic dialysis, correlating with increased cardiovascular death risk.
• Vitamin D receptor (VDR) activation shows potential in reducing morbidity and mortality, supported by retrospective studies.
• Calcimimetics (CaSR activators) improve mineral metabolism (Ca-P-PTH) and patient adherence to guidelines, with ongoing research into their clinical impact.

Impact:

• VDR and CaSR activators represent emerging therapeutic strategies for improving cardiovascular health in dialysis patients.
• These agents may offer a novel approach to mitigate the high rates of cardiovascular and all-cause mortality in this vulnerable population.
• Further research into VDR and CaSR activators could lead to improved patient management and better long-term outcomes for individuals with chronic kidney disease on dialysis.